| HOME >> MEDICINE >> TECHNOLOGY |
In clinical trials of AMITIZA (24 mcg) in patients with Chronic Idiopathic Constipation, the most common adverse reactions (incidence > 4%) were nausea (29%), diarrhea (12%), headache (11%), abdominal pain (8%), abdominal distention (6%), and flatulence (6%).
In clinical trials of AMITIZA (8 mcg) in patients with Irritable Bowel Syndrome with Constipation, the most common adverse reactions (incidence > 4%) were nausea (8%), diarrhea (7%), and abdominal pain (5%).
Please see complete Prescribing Information at http://www.amitiza.com.
AMITIZA is co-marketed by Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, Md., focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.
Sucampo Pharmaceuticals is marketing AMITIZA(R) (lubiprostone) in the
U.S. for Chronic Idiopathic Constipation in adults and Irritable Bowel
Syndrome with Constipation in women 18 years of age and older and is
developing the drug for additional gastrointestinal disorders with large
potential markets. In addition, Sucampo Pharmaceuticals has a robust
pipeline of compounds with the potential to target underserved diseases
affecting millions of patients worldwide. Sucampo Pharm
'/>"/>
| SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals, Copyright©2008 PR Newswire. All rights reserved |